Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ImmuCell Corporation (ICCC : NSDQ)
 
 • Company Description   
ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibodytechnology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea.

Number of Employees: 67

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.11 Daily Weekly Monthly
20 Day Moving Average: 17,614 shares
Shares Outstanding: 7.74 (millions)
Market Capitalization: $62.79 (millions)
Beta: 0.66
52 Week High: $10.96
52 Week Low: $7.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.39% -1.08%
12 Week -1.10% 6.89%
Year To Date 1.37% 20.07%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
56 EVERGREEN DR
-
PORTLAND,ME 04103
USA
ph: 207-878-2770
fax: 207-878-2117
iccc@lythampartners.com http://www.immucell.com
 
 • General Corporate Information   
Officers
Michael F. Brigham - Chief Executive Officer; President; Principal Fi
Gloria J. Basse - Director
Bobbi Jo Brockmann - Director
David S. Cunningham - Director
Steven T. Rosgen - Director

Peer Information
ImmuCell Corporation (BJCT)
ImmuCell Corporation (CADMQ)
ImmuCell Corporation (APNO)
ImmuCell Corporation (UPDC)
ImmuCell Corporation (IMTIQ)
ImmuCell Corporation (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 452525306
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 7.74
Most Recent Split Date: 7.00 (0.01:1)
Beta: 0.66
Market Capitalization: $62.79 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 57.93
PEG Ratio: -
Price Ratios
Price/Book: 1.88
Price/Cash Flow: 26.26
Price / Sales: 2.97
EPS Growth
vs. Year Ago Period: 250.00%
vs. Previous Quarter: 800.00%
Sales Growth
vs. Year Ago Period: 46.09%
vs. Previous Quarter: 10.21%
ROE
03/31/22 - 3.36
12/31/21 - -0.25
09/30/21 - 0.12
ROA
03/31/22 - 2.45
12/31/21 - -0.18
09/30/21 - 0.09
Current Ratio
03/31/22 - 7.78
12/31/21 - 6.42
09/30/21 - 7.42
Quick Ratio
03/31/22 - 6.32
12/31/21 - 5.20
09/30/21 - 6.19
Operating Margin
03/31/22 - 5.20
12/31/21 - -0.41
09/30/21 - 0.21
Net Margin
03/31/22 - 5.20
12/31/21 - -0.41
09/30/21 - 0.21
Pre-Tax Margin
03/31/22 - 5.25
12/31/21 - -0.36
09/30/21 - 0.28
Book Value
03/31/22 - 4.31
12/31/21 - 4.21
09/30/21 - 4.19
Inventory Turnover
03/31/22 - 3.78
12/31/21 - 4.11
09/30/21 - 4.22
Debt-to-Equity
03/31/22 - 0.30
12/31/21 - 0.26
09/30/21 - 0.26
Debt-to-Capital
03/31/22 - 23.02
12/31/21 - 20.36
09/30/21 - 20.85
 

Powered by Zacks Investment Research ©